TargetRNA is at the forefront of drug discovery, focusing on the development of novel therapeutics that target disease-causing RNA. The company recognizes that dysregulated RNA plays a critical role in many human diseases, and thus, it aims to create drugs that can bind directly to RNA molecules. This approach not only alters the RNA's structure but also its function, providing a pathway to potentially cure various diseases. The understanding of RNA's biological function is enhanced by considering its nucleotide sequence, secondary structure, and three-dimensional conformation, which are all crucial for effective drug design.

To facilitate its drug discovery efforts, TargetRNA employs a sophisticated platform that integrates nuclear magnetic resonance (NMR) spectroscopy with computational modeling. This platform utilizes NMR-derived ligand binding data to inform molecular dynamics simulations, allowing for the construction of accurate structural models of RNA. By leveraging this iterative biophysics and computational engine, TargetRNA aims to overcome historical challenges in RNA drug development, thereby increasing the success rate of lead compounds entering preclinical testing. This innovative approach positions TargetRNA to address a wide range of diseases linked to RNA dysregulation.

United States

Employs an iterative biophysics and computational engine that addresses the challenges and limitations that have historically hampered efforts to drug RNA. Utilizes NMR (nuclear magnetic resonance spectroscopy)-derived ligand binding data to guide molecular dynamics simulations and build accurate structural models.

TargetRNA

Company Details